Published in Hepatitis Weekly, January 14th, 2008
"In an open label, randomized, parallel group study, the liquid HV vaccine (HEXAVACO) (diphtheria, tetanus, 2-component acellular pertussis, inactivated poliomyelitis vaccine, Haemophilus influenzae type b conjugated to tetanus protein and hepatitis 13) was administered at 2, 4, 6, and 12 months...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.